Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YK-CD19-22-Boom
- Development stage
- Phase 1
- Lead developer
- Shanghai YaKe Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**YK-CD19-22-Boom** is an investigational dual-target chimeric antigen receptor T-cell therapy directed against CD19 and CD22, B-cell lineage antigens expressed on malignant B cells. The product is administered by infusion and is intended to enable engineered T cells to recognize and eliminate CD19-positive and CD22-positive hematologic cancer cells, potentially reducing relapse driven by loss of either single antigen. It was studied by the First Affiliated Hospital, Zhejiang University School of Medicine in a registered Phase 1 clinical study for CD19-positive/CD22-positive hematologic malignancies, including leukemia and lymphoma.
- Brand names
- BoomTM
- Other names
- CD19/CD22 CAR-TYaKe Biotechnology CD19/CD22 CAR-T cell therapy
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on YK-CD19-22-Boom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YK-CD19-22-Boom.